Insight Molecular Diagnostics (IMDX) Equity Ratio (2020 - 2025)
Historic Equity Ratio for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 0.21.
- Insight Molecular Diagnostics' Equity Ratio fell 25133.55% to 0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.21, marking a year-over-year decrease of 25133.55%. This contributed to the annual value of 0.35 for FY2024, which is 22801.89% down from last year.
- Per Insight Molecular Diagnostics' latest filing, its Equity Ratio stood at 0.21 for Q3 2025, which was down 25133.55% from 0.02 recorded in Q2 2025.
- Insight Molecular Diagnostics' 5-year Equity Ratio high stood at 0.82 for Q1 2021, and its period low was 0.35 during Q4 2024.
- In the last 5 years, Insight Molecular Diagnostics' Equity Ratio had a median value of 0.34 in 2022 and averaged 0.3.
- As far as peak fluctuations go, Insight Molecular Diagnostics' Equity Ratio skyrocketed by 3397.3% in 2021, and later crashed by 25133.55% in 2025.
- Insight Molecular Diagnostics' Equity Ratio (Quarter) stood at 0.41 in 2021, then fell by 16.18% to 0.34 in 2022, then fell by 20.23% to 0.27 in 2023, then plummeted by 228.02% to 0.35 in 2024, then soared by 40.18% to 0.21 in 2025.
- Its Equity Ratio stands at 0.21 for Q3 2025, versus 0.02 for Q2 2025 and 0.17 for Q1 2025.